THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

MAIA Biotechnology (MAIA) announced the publication of preclinical data for its lead proprietary telomere-targeting THIO dimer in the ...

THIO is presently developed as a third line of treatment for NSCLC for patients that are resistant to checkpoint inhibitors and chemotherapy. About MAIA Biotechnology, Inc. MAIA is a targeted ...

MAIA Biotechnology (MAIA) announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer NSCLC . Following successful outcomes to date in THIO-101 ...

MAIA Biotechnology receives USAN Council approval for “ateganosine” as nonproprietary name for anticancer agent THIO: Chicago Friday, March 21, 2025, 14:00 Hrs [IST] MAIA Biot ...

The THIO-101 study in 3L will enroll up to 48 ... please visit ClinicalTrials.gov using the identifier NCT05208944. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology ...

CHICAGO, March 20, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... preclinical data for its lead proprietary telomere-targeting THIO dimer in the peer-reviewed scientific journal Naunyn ...

CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer (NSCLC).

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug ...